Phase II study of combination bortezomib (Velcade PS-341) and rituximab in patients with relapsed/refractory Waldenstrom's macroglobulinemia.
Phase of Trial: Phase II
Latest Information Update: 30 Jan 2018
At a glance
- Drugs Bortezomib (Primary) ; Rituximab (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 27 Dec 2017 Status changed from active, no longer recruiting to completed.
- 31 Jul 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2017.
- 16 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 May 2017.